Related Experiment Video
Updated: Jan 28, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Rapid subcutaneous desensitization for the management of delayed hypersensitivity reactions to omalizumab:A case
1Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, China.
What Is Known And Objective:
Omalizumab is effective as an add-on drug to treat severe persistent allergic asthma. However, delayed hypersensitivity reactions to omalizumab may deprive patients of its use. Rapid subcutaneous desensitization could be a solution.
Case Description:
A 61-year-old man developed a delayed allergy to omalizumab after the first injection. A 14-step desensitization procedure was applied to the patient and was successful.
What Is New And Conclusion:
Delayed hypersensitivity reactions to omalizumab are rare, but they may cause the interruption of drug usage. Desensitization to omalizumab could be a possible solution.
Related Concept Videos
GPCR Desensitization
Desensitization and Tachyphylaxis
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Allergic Reactions
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:

